Evidence map›Paper›PMID 38828050›Full record

ArticleJournal of inflammation research2024

Significance of Multiple Lymphocyte-to-C-Reactive Protein Ratios in Predicting Long-Term Major Cardiovascular Adverse Events in Emergency Percutaneous Coronary Intervention Patients with ST-Segment Elevation Myocardial Infarction.

Jiangping Ye, Dongxia Xu, Rikang Yuan, Shaoqing Cao, Zhangyu Wang, Yuqin Wang, Chengsi Li, Gangjun Zong

Abstract read
In one paragraph

Article in Journal of inflammation research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jiangping YeWuxi Clinical College of Anhui Medical University, Wuxi, Jiangsu, People's Republic of China.
Dongxia XuWuxi Clinical College of Anhui Medical University, Wuxi, Jiangsu, People's Republic of China.
Rikang YuanWuxi Clinical College of Anhui Medical University, Wuxi, Jiangsu, People's Republic of China.
Shaoqing CaoWuxi Clinical College of Anhui Medical University, Wuxi, Jiangsu, People's Republic of China.
Zhangyu WangWuxi Clinical College of Anhui Medical University, Wuxi, Jiangsu, People's Republic of China.
Yuqin WangWuxi Clinical College of Anhui Medical University, Wuxi, Jiangsu, People's Republic of China.
Chengsi LiWuxi Clinical College of Anhui Medical University, Wuxi, Jiangsu, People's Republic of China.
Gangjun ZongWuxi Clinical College of Anhui Medical University, Wuxi, Jiangsu, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: The high morbidity and mortality associated with ST-segment elevation myocardial infarction (STEMI) are an urgent concern. This study aimed to investigate the ratio of lymphocyte count to C-reactive protein ratio (LCR) in multiple measurements in the perioperative period, exploring dynamic changes as the best predictor of major adverse cardiovascular events (MACE) in STEMI patients. Methods: We enrolled 205 STEMI patients, conducting blood counts at admission, 24 hours post-percutaneous coronary intervention (PCI), and at discharge. Cox proportional risk models evaluated factors independently associated with STEMI prognosis. The receiver operating characteristic (ROC) curve and the De-Long test determined the best predictor. Kaplan-Meier analysis assessed the prognostic value of LCR for STEMI patients. Statistical differences and correlations between LCR at 24 hours post-PCI and cardiovascular disease risk factors were also analyzed. Results: Gensini score (HR, 1.015; 95% CI, 1.007-1.022; Conclusion: LCR at 24 hours post-PCI may be a superior marker for long-term MACE prediction in STEMI patients, serving as the best predictor for distant MACE occurrence.

Indexed as

C-reactive proteinlymphocytemajor cardiovascular adverse eventspercutaneous coronary interventionST-segment elevation myocardial infarction

Identifiers

PMID38828050
PMCPMC11141709

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.